While the presence of the BIM deletion reduces the first-line response to imatinib in CML patients [19], in EGFR-NSCLC patients it predicts an inferior OS compared to individuals without the deletion (28.8 vs 40.2 months respectively, p<0.017) [20]. This evidence concerns the gene BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive.